Developer docs
API playgroundTry for free, no card

Search company profiles

IGEA S.p.A.

Full company profile

uuid004mg5i

Namestring
IGEA S.p.A.
Legal namestring
IGEA S.p.A.
Websiteurl
igeamedical.com
Company typeenum
Private
Founded yearint
1982
Descriptiontext

IGEA S.p.A. is a privately-held Italian biomedical company headquartered in Carpi, Modena, that designs, manufactures, and distributes proprietary medical devices for biophysical therapy across three divisions: orthopaedic therapies, electrochemotherapy, and gene therapies. The company builds pulsed electromagnetic field (PEMF), capacitive coupling electric field (CCEF), low-intensity pulsed ultrasound (LIPUS), and reversible electroporation devices — including Biostim, OsteoSpine, I-ONE, Biostim SPT, OsteoBit, FAST, Cliniporator, Cliniporator Vitae, CLINIPORATOR FULL, and Genedrive — that deliver patented, indication-specific signal parameters engineered to stimulate bone and cartilage repair, treat solid tumours, and enable nucleic acid vaccine delivery. All therapeutic signals are patented, supported by four decades of preclinical and clinical research conducted in collaboration with named institutions including the Rizzoli Orthopaedic Institute and the Universities of Modena, Naples, and Verona, with over 500,000 patients treated cumulatively.

IGEA sells and rents these devices to hospitals, clinics, and orthopaedic treatment centers through a direct field sales motion supplemented by a European distribution network covering 17+ countries (Austria, Belgium, Czech Republic, France, Germany, Greece, Ireland, Italy, Malta, Northern Ireland, Poland, Portugal, Romania, Scotland, Spain, the Netherlands, and the UK). Revenue is generated through one-time device purchases and a 'Rent or Buy' monthly subscription rental model, with a dedicated Medical Department supporting healthcare professional engagement and clinical evidence dissemination. The company was founded by Dr. Ruggero Cadossi, who continues to lead as Chair, Medical Director, and R&D Director alongside a medically credentialed senior team. IGEA has no disclosed institutional investors, no public listing, and reports 177 employees with no published financials.

Short descriptiontext

IGEA S.p.A. is an Italian privately-held biomedical company that develops and sells proprietary biophysical therapy devices (PEMF, CCEF, LIPUS, electroporation) across orthopaedics, electrochemotherapy, and gene therapies, serving hospitals and clinics in 17+ European countries through direct sales and a rental subscription model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCarpi (MO), Italy
HQ citystring
Carpi (MO)
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biophysical therapy devices, orthopaedic medical devices, electrochemotherapy equipment, bone healing devices, gene electroporation systems
Industry2 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKALAM
Pain Management (Spine & Musculoskeletal)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code3 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Biophysical Therapy Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of proprietary biophysical therapy medical devices including Biostim, OsteoSpine, I-ONE, Biostim SPT, OsteoBit, FAST for orthopaedics, Cliniporator for electrochemotherapy, and gene therapy equipment. Products are sold directly to healthcare facilities and hospitals.

igeamedical.com
2Device Rental
TypeLicensing Royalties
Description

The company offers a 'Rent or Buy' model allowing healthcare facilities to rent medical devices rather than purchase outright, providing flexible access to biophysical therapy equipment.

igeamedical.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Pricing details2 tiers
1Purchase option for medical devices
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Direct purchase of devices available through the website with quote request functionality.

igeamedical.com
2Rental option for medical devices
ModelSubscriptionBilling cadenceMonthly
igeamedical.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1IGEA Medical
Description

The commercial/trade name used for the company's medical device and biophysical therapy business operations.

igeamedical.com
Core offering1 text field

IGEA S.p.A. develops, manufactures and sells proprietary biophysical therapy medical devices across three therapeutic divisions: Orthopaedic Therapies (Biostim®, OsteoSpine®, I-ONE®, Biostim® SPT, OsteoBit®, FAST®) using PEMF, CCEF and LIPUS physical stimuli to promote bone and cartilage healing; Electrochemotherapy (Cliniporator®, Cliniporator® Vitae) using reversible electroporation for treatment of solid tumours and vascular malformations; and Gene Therapies (CLINIPORATOR® FULL, Genedrive) using tissue electroporation for nucleic acid vaccine delivery. The devices are sold and rented to hospitals, clinics and orthopaedic treatment centers, primarily across Europe.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

IGEA S.p.A. is a biomedical company and world leader in biophysical therapies, offering a portfolio of medical devices across three therapeutic divisions: Orthopaedic Therapies (Biostim®, OsteoSpine®, I-ONE®, Biostim® SPT, OsteoBit®, FAST®), Electrochemotherapy (Cliniporator®, Cliniporator® Vitae, Electrodes), and Gene Therapies (CLINIPORATOR® FULL, Genedrive, Electrodes and Accessories). These products utilize physical energy modalities including Pulsed Electromagnetic Fields (PEMF), Capacitive Coupling Electric Fields (CCEF), Low-Intensity Pulsed Ultrasound (LIPUS), and reversible electroporation for therapeutic purposes in orthopaedic, oncological, and genetic medicine applications.

Product and service10 records
1Biostim®
CategoryOrthopaedic biophysical therapy device
Description

Pulsed Electromagnetic Field (PEMF) therapy device for osteogenesis stimulation, promoting bone tissue repair and accelerating fracture healing. Targeted at orthopaedic departments in hospitals and clinics.

2OsteoSpine®
CategoryOrthopaedic biophysical therapy device
Description

Capacitive Coupling Electric Field (CCEF) therapy device for the treatment of osteoporotic vertebral fractures and control of acute and chronic pain. Targeted at orthopaedic and spine specialists.

3I-ONE®
CategoryOrthopaedic biophysical therapy device
Description

Pulsed Electromagnetic Field (PEMF) therapy device with a joint-specific signal for control of the articular environment, treating knee bone edema, osteoarthritis and supporting cartilage repair. Targeted at orthopaedic specialists and rheumatologists.

4Biostim® SPT
CategoryOrthopaedic biophysical therapy device
Description

Pulsed Electromagnetic Field (PEMF) therapy device for osteogenesis stimulation, specifically designed for revision hip replacement recovery and osteonecrosis treatment. Targeted at orthopaedic surgery departments.

5OsteoBit®
CategoryOrthopaedic biophysical therapy device
Description

Capacitive Coupling Electric Field (CCEF) therapy device for treatment of fresh and unoperated fractures, delayed union, pseudarthrosis, and stress fractures. Targeted at trauma and orthopaedic departments.

6FAST®
CategoryOrthopaedic biophysical therapy device
Description

Low-Intensity Pulsed Ultrasound (LIPUS) therapy device for accelerated healing of recent tibia fractures, delayed unions, and pseudarthrosis. Targeted at orthopaedic and trauma clinics.

7Cliniporator®
CategoryElectrochemotherapy device
Description

Electrochemotherapy device utilising reversible electroporation for the treatment of primary and secondary solid tumours. Targeted at surgical oncology departments and cancer centers.

8Cliniporator® Vitae
CategoryElectrochemotherapy device
Description

Electrochemotherapy device for tumour treatment and vascular malformations using reversible electroporation technology. Targeted at oncology and vascular surgery departments.

9CLINIPORATOR® FULL
CategoryGene therapy electroporation device
Description

Gene therapy device for tissue electroporation enabling delivery of nucleic acid vaccines and therapeutic applications. Targeted at gene therapy research labs and translational research centers.

10Genedrive
CategoryGene therapy electroporation device
Description

Gene therapy technology platform for electroporation-based delivery of genetic material. Targeted at research hospitals, biotech laboratories and translational research teams.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major orthopedic devices conglomerate with biologic and regenerative adjacencies. Broad incumbent in the orthopaedic space that competes for hospital orthopaedic budgets targeted by IGEA's portfolio.

TypeEmerging player
Description

DNA vaccine and gene therapy developer using electroporation delivery (CELLECTRA). Comparable to IGEA's gene therapy electroporation platform (CLINIPORATOR FULL, Genedrive) for nucleic acid vaccination.

TypeEmerging player
Description

Medical device company with NanoKnife irreversible electroporation technology for tumor ablation. Adjacent to IGEA's reversible electroporation (Cliniporator) in the electroporation oncology space.

TypeDirect peer
Description

Orthobiologics and bone stimulation company with EXOGEN ultrasound (LIPUS-equivalent) and electrical stimulation products. Highly comparable to IGEA's FAST (LIPUS) and PEMF devices in clinical indication and care setting.

TypeDirect peer
Description

US-listed orthopedic medical device company with a leading bone growth stimulation (PEMF and direct current) portfolio. Directly comparable to IGEA's Biostim, Biostim SPT, and OsteoBit orthopaedic stimulation devices, addressing fracture healing, non-union, and spine fusion indications.

6OncoSec Medical
TypeEmerging player
Description

Biotech focused on intratumoral electroporation and gene delivery (ImmunoPulse/TAVO). Comparable to IGEA's Cliniporator electroporation platform for oncology and gene therapy applications.

TypeBroad incumbent
Description

Global orthopedic medtech incumbent that distributes bone stimulation and biologic solutions for fracture healing. Broader portfolio player with overlapping orthopaedic stimulation offerings.

TypeBroad incumbent
Description

Large orthopedic and recovery sciences platform including bone growth stimulation devices (e.g., CMF Ol1000, SpinalStim). Comparable as a broad incumbent offering overlapping PEMF/electrical stimulation capabilities within a much larger portfolio.

TypeDirect peer
Description

Japanese manufacturer of PEMF and physical therapy medical devices (e.g., Ito Ultralizer, PEMF bone healing devices). Closely comparable biophysical stimulation technology with overlap in orthopaedic indications.

10BTL Group
TypeDirect peer
Description

Medical device company offering PEMF-based devices (e.g., BTL-5110) for orthopaedics and rehabilitation, alongside physiotherapy and aesthetics devices. Direct competitor in biophysical electromagnetic therapy for musculoskeletal indications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IGEA S.p.A.

Biophysical Therapy Medical Devicesigeamedical.com

IGEA S.p.A. is an Italian privately-held biomedical company that develops and sells proprietary biophysical therapy devices (PEMF, CCEF, LIPUS, electroporation) across orthopaedics, electrochemotherapy, and gene therapies, serving hospitals and clinics in 17+ European countries through direct sales and a rental subscription model.

What IGEA S.p.A. does

IGEA S.p.A. is a privately-held Italian biomedical company headquartered in Carpi, Modena, that designs, manufactures, and distributes proprietary medical devices for biophysical therapy across three divisions: orthopaedic therapies, electrochemotherapy, and gene therapies. The company builds pulsed electromagnetic field (PEMF), capacitive coupling electric field (CCEF), low-intensity pulsed ultrasound (LIPUS), and reversible electroporation devices — including Biostim, OsteoSpine, I-ONE, Biostim SPT, OsteoBit, FAST, Cliniporator, Cliniporator Vitae, CLINIPORATOR FULL, and Genedrive — that deliver patented, indication-specific signal parameters engineered to stimulate bone and cartilage repair, treat solid tumours, and enable nucleic acid vaccine delivery. All therapeutic signals are patented, supported by four decades of preclinical and clinical research conducted in collaboration with named institutions including the Rizzoli Orthopaedic Institute and the Universities of Modena, Naples, and Verona, with over 500,000 patients treated cumulatively.

IGEA sells and rents these devices to hospitals, clinics, and orthopaedic treatment centers through a direct field sales motion supplemented by a European distribution network covering 17+ countries (Austria, Belgium, Czech Republic, France, Germany, Greece, Ireland, Italy, Malta, Northern Ireland, Poland, Portugal, Romania, Scotland, Spain, the Netherlands, and the UK). Revenue is generated through one-time device purchases and a 'Rent or Buy' monthly subscription rental model, with a dedicated Medical Department supporting healthcare professional engagement and clinical evidence dissemination. The company was founded by Dr. Ruggero Cadossi, who continues to lead as Chair, Medical Director, and R&D Director alongside a medically credentialed senior team. IGEA has no disclosed institutional investors, no public listing, and reports 177 employees with no published financials.

IGEA S.p.A. firmographics

Firmographics
Name
IGEA S.p.A.
Legal name
IGEA S.p.A.
Website
https://igeamedical.com
Company type
Private
Founded year
1982
Operating status
Operating
Headcount range
101–250 employees
Short description
IGEA S.p.A. is an Italian privately-held biomedical company that develops and sells proprietary biophysical therapy devices (PEMF, CCEF, LIPUS, electroporation) across orthopaedics, electrochemotherapy, and gene therapies, serving hospitals and clinics in 17+ European countries through direct sales and a rental subscription model.
Ownership category
akta.pro rank

IGEA S.p.A. industry classification

Industry
Product category
Biophysical Therapy Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKALAM
Pain Management (Spine & Musculoskeletal)

Keywords

  • Biophysical therapy devices
  • Orthopaedic medical devices
  • Electrochemotherapy equipment
  • Bone healing devices
  • Gene electroporation systems

Where IGEA S.p.A. is headquartered

Location

Headquarters

HQ city
Carpi (MO)
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

IGEA S.p.A. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Sale of proprietary biophysical therapy medical devices including Biostim, OsteoSpine, I-ONE, Biostim SPT, OsteoBit, FAST for orthopaedics, Cliniporator for electrochemotherapy, and gene therapy equipment. Products are sold directly to healthcare facilities and hospitals.
  2. Device Rental: The company offers a 'Rent or Buy' model allowing healthcare facilities to rent medical devices rather than purchase outright, providing flexible access to biophysical therapy equipment.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractPurchase option for medical devices
SubscriptionMonthlyRental option for medical devices

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

IGEA S.p.A. product offering

Product offering

Core offering

IGEA S.p.A. develops, manufactures and sells proprietary biophysical therapy medical devices across three therapeutic divisions: Orthopaedic Therapies (Biostim®, OsteoSpine®, I-ONE®, Biostim® SPT, OsteoBit®, FAST®) using PEMF, CCEF and LIPUS physical stimuli to promote bone and cartilage healing; Electrochemotherapy (Cliniporator®, Cliniporator® Vitae) using reversible electroporation for treatment of solid tumours and vascular malformations; and Gene Therapies (CLINIPORATOR® FULL, Genedrive) using tissue electroporation for nucleic acid vaccine delivery. The devices are sold and rented to hospitals, clinics and orthopaedic treatment centers, primarily across Europe.

Product overview

IGEA S.p.A. is a biomedical company and world leader in biophysical therapies, offering a portfolio of medical devices across three therapeutic divisions: Orthopaedic Therapies (Biostim®, OsteoSpine®, I-ONE®, Biostim® SPT, OsteoBit®, FAST®), Electrochemotherapy (Cliniporator®, Cliniporator® Vitae, Electrodes), and Gene Therapies (CLINIPORATOR® FULL, Genedrive, Electrodes and Accessories). These products utilize physical energy modalities including Pulsed Electromagnetic Fields (PEMF), Capacitive Coupling Electric Fields (CCEF), Low-Intensity Pulsed Ultrasound (LIPUS), and reversible electroporation for therapeutic purposes in orthopaedic, oncological, and genetic medicine applications.

Differentiator

Problem solved

Functional benefit

Brands

  • IGEA Medical: The commercial/trade name used for the company's medical device and biophysical therapy business operations.

Products and services

  • Biostim® Pulsed Electromagnetic Field (PEMF) therapy device for osteogenesis stimulation, promoting bone tissue repair and accelerating fracture healing. Targeted at orthopaedic departments in hospitals and clinics.
  • OsteoSpine® Capacitive Coupling Electric Field (CCEF) therapy device for the treatment of osteoporotic vertebral fractures and control of acute and chronic pain. Targeted at orthopaedic and spine specialists.
  • I-ONE® Pulsed Electromagnetic Field (PEMF) therapy device with a joint-specific signal for control of the articular environment, treating knee bone edema, osteoarthritis and supporting cartilage repair. Targeted at orthopaedic specialists and rheumatologists.
  • Biostim® SPT Pulsed Electromagnetic Field (PEMF) therapy device for osteogenesis stimulation, specifically designed for revision hip replacement recovery and osteonecrosis treatment. Targeted at orthopaedic surgery departments.
  • OsteoBit® Capacitive Coupling Electric Field (CCEF) therapy device for treatment of fresh and unoperated fractures, delayed union, pseudarthrosis, and stress fractures. Targeted at trauma and orthopaedic departments.
  • FAST® Low-Intensity Pulsed Ultrasound (LIPUS) therapy device for accelerated healing of recent tibia fractures, delayed unions, and pseudarthrosis. Targeted at orthopaedic and trauma clinics.
  • Cliniporator® Electrochemotherapy device utilising reversible electroporation for the treatment of primary and secondary solid tumours. Targeted at surgical oncology departments and cancer centers.
  • Cliniporator® Vitae Electrochemotherapy device for tumour treatment and vascular malformations using reversible electroporation technology. Targeted at oncology and vascular surgery departments.
  • CLINIPORATOR® FULL Gene therapy device for tissue electroporation enabling delivery of nucleic acid vaccines and therapeutic applications. Targeted at gene therapy research labs and translational research centers.
  • Genedrive Gene therapy technology platform for electroporation-based delivery of genetic material. Targeted at research hospitals, biotech laboratories and translational research teams.

Companies that use IGEA S.p.A.

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

IGEA S.p.A. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

IGEA S.p.A. partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

IGEA S.p.A. competitors and assessment

Company assessment

Broad incumbents

  • Stryker: Major orthopedic devices conglomerate with biologic and regenerative adjacencies. Broad incumbent in the orthopaedic space that competes for hospital orthopaedic budgets targeted by IGEA's portfolio.
  • Zimmer Biomet: Global orthopedic medtech incumbent that distributes bone stimulation and biologic solutions for fracture healing. Broader portfolio player with overlapping orthopaedic stimulation offerings.
  • Enovis (DJO Global): Large orthopedic and recovery sciences platform including bone growth stimulation devices (e.g., CMF Ol1000, SpinalStim). Comparable as a broad incumbent offering overlapping PEMF/electrical stimulation capabilities within a much larger portfolio.

Emerging players

  • Inovio Pharmaceuticals: DNA vaccine and gene therapy developer using electroporation delivery (CELLECTRA). Comparable to IGEA's gene therapy electroporation platform (CLINIPORATOR FULL, Genedrive) for nucleic acid vaccination.
  • AngioDynamics: Medical device company with NanoKnife irreversible electroporation technology for tumor ablation. Adjacent to IGEA's reversible electroporation (Cliniporator) in the electroporation oncology space.
  • OncoSec Medical: Biotech focused on intratumoral electroporation and gene delivery (ImmunoPulse/TAVO). Comparable to IGEA's Cliniporator electroporation platform for oncology and gene therapy applications.

Direct peers

  • Bioventus: Orthobiologics and bone stimulation company with EXOGEN ultrasound (LIPUS-equivalent) and electrical stimulation products. Highly comparable to IGEA's FAST (LIPUS) and PEMF devices in clinical indication and care setting.
  • Orthofix Medical: US-listed orthopedic medical device company with a leading bone growth stimulation (PEMF and direct current) portfolio. Directly comparable to IGEA's Biostim, Biostim SPT, and OsteoBit orthopaedic stimulation devices, addressing fracture healing, non-union, and spine fusion indications.
  • Ito Co., Ltd. Japanese manufacturer of PEMF and physical therapy medical devices (e.g., Ito Ultralizer, PEMF bone healing devices). Closely comparable biophysical stimulation technology with overlap in orthopaedic indications.
  • BTL Group: Medical device company offering PEMF-based devices (e.g., BTL-5110) for orthopaedics and rehabilitation, alongside physiotherapy and aesthetics devices. Direct competitor in biophysical electromagnetic therapy for musculoskeletal indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

IGEA S.p.A. social profiles

Digital presence

IGEA S.p.A. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IGEA S.p.A. leadership team

Management profile

Number of profiles

Profiles4 records

IGEA S.p.A. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IGEA S.p.A. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IGEA S.p.A.

What does IGEA S.p.A. do?

IGEA S.p.A. develops, manufactures and sells proprietary biophysical therapy medical devices across three therapeutic divisions: Orthopaedic Therapies (Biostim®, OsteoSpine®, I-ONE®, Biostim® SPT, OsteoBit®, FAST®) using PEMF, CCEF and LIPUS physical stimuli to promote bone and cartilage healing; Electrochemotherapy (Cliniporator®, Cliniporator® Vitae) using reversible electroporation for treatment of solid tumours and vascular malformations; and Gene Therapies (CLINIPORATOR® FULL, Genedrive) using tissue electroporation for nucleic acid vaccine delivery. The devices are sold and rented to hospitals, clinics and orthopaedic treatment centers, primarily across Europe.

Is IGEA S.p.A. a public or private company?

IGEA S.p.A. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was IGEA S.p.A. founded?

IGEA S.p.A. was founded in 1982. It employs 101 to 250 people.

Where is IGEA S.p.A. based?

IGEA S.p.A. is headquartered in Carpi (MO), Italy, in the Europe region.

How does IGEA S.p.A. make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are device Rental.

Who are IGEA S.p.A.'s main competitors?

Broad incumbents on record are Stryker, Zimmer Biomet and Enovis (DJO Global). Emerging players are Inovio Pharmaceuticals, AngioDynamics and OncoSec Medical. Direct peers are Bioventus, Orthofix Medical, Ito Co., Ltd. and BTL Group.

Does IGEA S.p.A. have an API?

No public API is recorded for IGEA S.p.A..

What industry is IGEA S.p.A. in?

IGEA S.p.A.'s product category is Biophysical Therapy Medical Devices. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAKALAM, Pain Management (Spine & Musculoskeletal). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical BiophysicsOncoSec Medical announced on Nov. 24, 2020 that it has licensed exclusive rights to the Cliniporator electroporation gene delivery platform from IGEA Clinical Biophysics, covering oncology gene delivery including its visceral lesion applicator program. The FDA has cleared Cliniporator for use in OncoSec's Phase 1 trial of CORVax12, a DNA-encodable SARS-CoV-2 spike vaccine combined with TAVO IL-12. Financial terms were not disclosed.PR NewswireSpine Bone Stimulator Market to Expand With 3.8% CAGR By 2024 | Key Players: IGEA S.p.A. & Orthofix Inc.: Radiant Insights, Inc.Radiant Insights, Inc. has published a market research report projecting the global spine bone stimulator market to grow at a CAGR of 3.8% during 2019–2024, driven by increasing geriatric populations and rising incidences of bone disorders such as osteoporosis and arthritis. The report identifies key players in the market including Elizur Corporation, Bioventus LLC, IGEA S.p.A., Medtronic Plc, Orthofix Inc., Smith & Nephew Plc, Stryker Corporation, and Zimmer Biomet Holdings Inc., with North America expected to account for a significant revenue share. Technological advances in healthcare, including electrical stimulation devices, are cited as growth drivers, while factors such as bone growth steroids and high initial device costs may restrain market expansion.